Skip to content
Faron, etusivu
Releases and publications
Careers
Contact Information
Search for:
LANGUAGE
English
Suomi
About
Management
Board of directors
Scientific Advisory Board
Sustainability
Pipeline
Our science
Clinical trials
Drug candidates
Investors
Faron as an investment
Strategy
Faron’s business
Market overview
Key financials
Forecasts and analysis, Analysts
Outlook
Share and shareholders
Share information
Shareholders
Share monitor
Management ownership and transactions
Warrants
Public offering 2024
AIM rule 26
Governance
Advisors
Articles of association
Auditor
Board committees
General Meeting
Insider management
Remuneration
Risk management and internal control
Reports and presentations
Investor relations
Disclosure policy
Investor calendar
Contact Information
For Patients
About
Management
Board of directors
Scientific Advisory Board
Sustainability
Pipeline
Our science
Clinical trials
Drug candidates
Investors
Faron as an investment
Strategy
Faron’s business
Market overview
Key financials
Forecasts and analysis, Analysts
Outlook
Share and shareholders
Share information
Shareholders
Share monitor
Management ownership and transactions
Warrants
Public offering 2024
AIM rule 26
Governance
Advisors
Articles of association
Auditor
Board committees
General Meeting
Insider management
Remuneration
Risk management and internal control
Reports and presentations
Investor relations
Disclosure policy
Investor calendar
Contact Information
For Patients
Releases and publications
Careers
Contact Information
Search for:
LANGUAGE
English
Suomi
releases and publications
Category
All
Company announcements
Press releases
Managers' transactions
Flagging notifications
Year
All
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
23.04.2021
Board Change
Regulatory
23.04.2021
Result of AGM
Regulatory
29.03.2021
Appointment of a Broker
Regulatory
25.03.2021
Exercise of Options
Regulatory
25.03.2021
Notice of Faron Pharmaceuticals Ltd’s AGM
Regulatory
25.03.2021
Faron´s Annual Report 2020 published
Regulatory
25.03.2021
Financial statement January 1 to December 31 2020
Regulatory
22.03.2021
Bexmarilimab (Clevegen) development update
Regulatory
11.03.2021
Faron to Present at Oppenheimer Conference
02.03.2021
Faron to Present at H.C. Wainwright Conference
Previous
Next
Back to top
